CZ20013307A3 - Farmaceutické kompozice obsahující komplexy kovů - Google Patents

Farmaceutické kompozice obsahující komplexy kovů Download PDF

Info

Publication number
CZ20013307A3
CZ20013307A3 CZ20013307A CZ20013307A CZ20013307A3 CZ 20013307 A3 CZ20013307 A3 CZ 20013307A3 CZ 20013307 A CZ20013307 A CZ 20013307A CZ 20013307 A CZ20013307 A CZ 20013307A CZ 20013307 A3 CZ20013307 A3 CZ 20013307A3
Authority
CZ
Czechia
Prior art keywords
bis
amd
ruthenium
methyl
complex
Prior art date
Application number
CZ20013307A
Other languages
Czech (cs)
English (en)
Inventor
Simon Fricker
Michael J. Abrams
Gary J. Bridger
Renato Skerlj
Ian Baird
Beth R. Cameron
Original Assignee
Anormed Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc. filed Critical Anormed Inc.
Publication of CZ20013307A3 publication Critical patent/CZ20013307A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046Ruthenium compounds
    • C07F15/0053Ruthenium compounds without a metal-carbon linkage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/295Iron group metal compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CZ20013307A 1999-03-19 2000-03-17 Farmaceutické kompozice obsahující komplexy kovů CZ20013307A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12516699P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
CZ20013307A3 true CZ20013307A3 (cs) 2002-05-15

Family

ID=22418482

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20013307A CZ20013307A3 (cs) 1999-03-19 2000-03-17 Farmaceutické kompozice obsahující komplexy kovů

Country Status (15)

Country Link
US (1) US20020049190A1 (https=)
EP (1) EP1163247A1 (https=)
JP (1) JP2004500321A (https=)
KR (1) KR20010112343A (https=)
CN (1) CN1391577A (https=)
AU (1) AU3268500A (https=)
BR (1) BR0011678A (https=)
CA (1) CA2367282A1 (https=)
CZ (1) CZ20013307A3 (https=)
HU (1) HUP0400457A2 (https=)
IL (1) IL145290A0 (https=)
MX (1) MXPA01009410A (https=)
NO (1) NO20014526L (https=)
PL (1) PL356683A1 (https=)
WO (1) WO2000056743A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1165576T3 (da) 1999-04-13 2006-03-27 Anormed Inc Fremgangsmåde til fremstilling af amin-platin-komplekser
JP4227701B2 (ja) * 1999-05-25 2009-02-18 中部キレスト株式会社 ジエチレントリアミン五酢酸ルテニウム二アンモニウム塩またはその水和物およびその製法
US6489638B2 (en) * 2000-06-23 2002-12-03 Semiconductor Energy Laboratory Co., Ltd. Light emitting device
US6894049B1 (en) 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7011854B2 (en) * 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
GB2395431A (en) * 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US7737179B2 (en) * 2003-08-04 2010-06-15 J&J Consumer Companies, Inc. Methods for treatment of dermatological conditions
PL1712547T3 (pl) * 2004-02-05 2012-04-30 Kyorin Seiyaku Kk Pochodna bicykloestrowa
FR2873037B1 (fr) * 2004-07-13 2008-04-11 Univ Pasteur Methodes et compositions pour le traitement de cancers
EP2447271A1 (en) * 2005-12-21 2012-05-02 F. Hoffmann-La Roche AG Redox mediators
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
EP1995237A4 (en) 2006-03-08 2011-07-06 Kyorin Seiyaku Kk PROCESS FOR PREPARING AN AMINOACETYLPYRROLIDINCARBONITRILE DERIVATIVE AND PRODUCTION PRODUCT THEREOF
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
WO2008038305A2 (en) * 2006-09-26 2008-04-03 Jegannathan Srinivas Therapeutical formulation comprising a thiazolidinedione and a nitric oxide scavenger.
US8143427B2 (en) 2007-03-22 2012-03-27 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative
KR20110084280A (ko) 2008-11-03 2011-07-21 알레시아 바이오쎄라퓨틱스 인코포레이티드 종양 항원의 생물 활성을 특이적으로 차단하는 항체
DE102010014412A1 (de) 2010-04-08 2012-04-19 Friedrich-Schiller-Universität Jena Verwendung von zweikernigen Eisenkomplexen mit schwefelhaltigen Liganden als pharmakologische Wirkstoffe
DE102010014411A1 (de) 2010-04-08 2011-10-13 Friedrich-Schiller-Universität Jena Kohlenmonoxid und Eisen freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
RS59080B1 (sr) 2011-03-31 2019-09-30 Adc Therapeutics Sa Antitela protiv antigena 1 povezanog sa bubrezima i njihovi fragmenti koji se vezuju za antigen
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
DE102012004132A1 (de) 2012-02-29 2013-08-29 Friedrich-Schiller-Universität Jena Kohlenstoffmonoxid freisetzende Materialien und deren Verwendung
DE102014008537A1 (de) 2014-06-04 2015-12-17 Friedrich-Schiller-Universität Jena Wasserlösliche manganbasierte Kohlenstoffmonoxid freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
US11420910B2 (en) * 2014-10-30 2022-08-23 Katholieke Universitet Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
CN113429456B (zh) * 2021-06-11 2022-05-31 首都医科大学 多肽衍生物钌类络合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721669A (en) * 1985-01-18 1988-01-26 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents
US5112974A (en) * 1985-01-18 1992-05-12 The Trustees Of Columbia University In The City Of New York Mixed ligand complexes and uses thereof as binding agents to DNA
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions
SE9703396D0 (sv) * 1997-09-19 1997-09-19 Lincoln Binuclear complex

Also Published As

Publication number Publication date
KR20010112343A (ko) 2001-12-20
PL356683A1 (en) 2004-06-28
CA2367282A1 (en) 2000-09-28
HUP0400457A2 (hu) 2004-05-28
IL145290A0 (en) 2002-06-30
NO20014526D0 (no) 2001-09-18
US20020049190A1 (en) 2002-04-25
EP1163247A1 (en) 2001-12-19
NO20014526L (no) 2001-10-16
JP2004500321A (ja) 2004-01-08
BR0011678A (pt) 2002-02-26
MXPA01009410A (es) 2003-06-06
WO2000056743A1 (en) 2000-09-28
AU3268500A (en) 2000-10-09
CN1391577A (zh) 2003-01-15

Similar Documents

Publication Publication Date Title
CZ20013307A3 (cs) Farmaceutické kompozice obsahující komplexy kovů
Zobi et al. CO releasing properties and cytoprotective effect of cis-trans-[ReII (CO) 2Br2L2] n complexes
US5824673A (en) Pharmaceutical compositions comprising metal complexes
US6417182B1 (en) Pharmaceutical compositions comprising metal complexes
Mészáros et al. An 8-hydroxyquinoline–proline hybrid with multidrug resistance reversal activity and the solution chemistry of its half-sandwich organometallic Ru and Rh complexes
WO2025108479A1 (en) Compounds for degradation or inhibition of kras mutant proteins and uses thereof
Chen et al. A ruthenium (II) β-carboline complex induced p53-mediated apoptosis in cancer cells
EP2016085B9 (en) Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis
Shtemenko et al. Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin
JP6316479B2 (ja) カルマンガホジピル、新たな化学実体、および他の混合金属錯体、調製の方法、組成物、および処置の方法
Wang et al. Cycloplatinated (II) complex based on isoquinoline alkaloid elicits ferritinophagy-dependent ferroptosis in triple-negative breast cancer cells
Lovison et al. Cationic carboxylate and thioacetate ruthenium (II) complexes: synthesis and cytotoxic activity against anaplastic thyroid cancer cells
Mathuber et al. Development of a cobalt (III)-based ponatinib prodrug system
AU2024220523B2 (en) Tetrazines with improved properties
JP2005501859A (ja) 白金錯体及びガンの処置におけるそれらの使用
Sharkawy et al. A novel benzothiazole-1, 2, 3-triazole-based arene osmium (II) complex as an effective rhabdomyosarcoma cancer stem cell agent
Mansour et al. A comprehensive survey of cytotoxic active half-sandwich Ir (III) complexes: structural perspective, and mechanism of action
Lu et al. Increasing the cytotoxicity of Ru (II) polypyridyl complexes by tuning the electron-donating ability of 1, 10-phenanthroline ligands
Richter et al. Platinum (ii/iv) complexes with N-substituted carboxylate ethylenediamine/propylenediamine ligands: preparation, characterization and in vitro activity
US20090175775A1 (en) Metal complexes having vitamin b12 as a ligand
Bartolucci et al. Five-coordinate platinum (II) complexes containing substituted olefins: synthesis and cytostatic activity
Radanovic et al. Synthesis and characterization of hexadentate cobalt (III) complexes with novel edta-type ligands. 1. Circular dichroism of a cobalt (III) complex of ethylenediamine-N-acetic-N, N', N'-tri-3-propionic acid
CN102603812B (zh) 一种双核铂(ⅱ)–唑来膦酸配合物及其制备和应用
Romani Emerging metal-organic anticancer compounds: synthesis and biological activity of novel Ga (III) and Ru (II) complexes
Icsel et al. Trans-Pd (II) and Pt (II) saccharinate complexes with S, S-diphenylsulfimide: Synthesis, structures, anticancer evaluation and molecular docking